Neutralization of the SARS-CoV-2 Delta variant after heterologous and homologous BNT162b2 or ChAdOx1 nCoV-19 vaccination
Swantje I. Hammerschmidt, Berislav Bošnjak, Günter Bernhardt, Michaela Friedrichsen, Inga Ravens, Alexandra Dopfer‐Jablonka, Markus Hoffmann, Stefan Pöhlmann, Georg M. N. Behrens, Reinhold Förster
Abstract
Since the beginning of the COVID-19 pandemic, divergent variants of concern (VoCs) of SARS-CoV-2 have evolved and become the most prevalent SARS-CoV-2 variants in distinct locations at different times. Currently, the Delta variant (B.1.617.2) dominates infection events in large parts of the world. Immunization campaigns, however, still use SARS-CoV-2 vaccines based on the spike (S) protein of the original Wuhan virus.
Topics & Concepts
HeterologousSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Coronavirus disease 2019 (COVID-19)Neutralization2019-20 coronavirus outbreakVirologyVaccinationBiologyComputational biologyComputer scienceMedicineGeneticsInfectious disease (medical specialty)VirusGeneOutbreakDiseasePathologySARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesHeparin-Induced Thrombocytopenia and Thrombosis